title: The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
abstract: Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.
authors.affiliation: Dept. of Medicine I, St. Josef-Hospital, Ruhr-Univ. Bochum, Gudrunstr. 56, 44791 Bochum, Germany. juris.meier@rub.de
authors.forename: Juris J
authors.initials: JJ
authors.lastname: Meier
authors.forename: Arnica
authors.initials: A
authors.lastname: Gethmann
authors.forename: Michael A
authors.initials: MA
authors.lastname: Nauck
authors.forename: Oliver
authors.initials: O
authors.lastname: Götze
authors.forename: Frank
authors.initials: F
authors.lastname: Schmitz
authors.forename: Carolyn F
authors.initials: CF
authors.lastname: Deacon
authors.forename: Baptist
authors.initials: B
authors.lastname: Gallwitz
authors.forename: Wolfgang E
authors.initials: WE
authors.lastname: Schmidt
authors.forename: Jens J
authors.initials: JJ
authors.lastname: Holst
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D005746:Gastric Emptying / Q000187:drug effects*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007328:Insulin / Q000097:blood*; D050356:Lipid Metabolism; D008297:Male; D010455:Peptides / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D010455:Peptides; C114437:glucagon-like peptide-1 (9-36)-amide; D052216:Glucagon-Like Peptide 1